• Biotin (Vitamin B7) in Motor and Metabolic Assays

  2026-09-26

  Use Biotin (Vitamin B7) to support carboxylase-focused metabolism studies and to control avidin–streptavidin steps in carefully designed assays. For kinesin experiments, distinguish free biotin from activated biotinylation reagents: the former can serve as a soluble competitor or control, while the latter is needed for covalent protein labeling.

• FPH1 (BRD-6125): Hepatocyte Assay Guide

  2026-09-25

  A practical guide to using FPH1 (BRD-6125) in hepatocyte proliferation and function workflows, with formulation, dosing, and interpretation considerations. Includes product-specific handling details for SKU B3701 and guidance for choosing fit-for-purpose readouts.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody

  2026-09-25

  This affinity-purified, HRP-labeled secondary antibody detects rabbit IgG primary antibodies in workflows such as Western blotting, ELISA, and immunohistochemistry. It supports research detection only; it is not intended for diagnostic or medical use, and assay-specific working dilutions should be established during validation.

• Zolmitriptan and Causal Assay Design

  2026-09-24

  Zolmitriptan is a 5-HT1B receptor agonist that helps researchers interrogate migraine-related signaling. This article focuses on a less-explored question: how to separate receptor engagement from downstream outcomes, using a lysosomal antiviral study to illustrate rigorous assay interpretation—not to imply a shared mechanism.

• GSK 2837808A for Reliable LDHA Assays

  2026-09-24

  Learn how GSK 2837808A (SKU B4929) can support carefully controlled LDHA and cancer-metabolism experiments, from viability-assay design to interpretation of lactate readouts. The guide distinguishes reported biochemical potency and hepatocellular carcinoma findings from questions that still require validation in other cell models.

• FPH1 (BRD-6125): Functional Hepatocyte Expansion

  2026-09-23

  FPH1 (BRD-6125) offers a way to study hepatocyte expansion alongside measures of differentiated function. This article explains how to interpret growth and functional readouts together—and how a separate light-controlled gene-regulation study informs assay design without implying a direct connection to FPH1.

• Pulchinenoside B4 Targets CD1d–NLRP3 Colitis

  2026-09-23

  A 2025 study shows that Pulchinenoside B4 protects against DSS-induced colitis by acting through a macrophage CD1d–NLRP3 inflammasome axis rather than by broadly suppressing intestinal inflammation. Its combination of knockout models, cell-specific analyses, biolayer interferometry, and CETSA connects CD1d to the AKT–STAT1–PRDX1–NF-κB pathway and provides a mechanistic framework for inflammation research.

• Beclin1, Ferroptosis, and Doxorubicin Liver Injury

  2026-09-22

  The reference study identifies Beclin1 as a contributor to doxorubicin-induced liver injury by linking excessive autophagy with ferroptotic lipid damage. Its loss-of-function and DHODH overexpression experiments suggest that the Beclin1–DHODH relationship may be an important regulatory axis connecting oxidative stress, iron handling, and hepatocyte injury.

• CHI3L1-IN-5 (Compound Z17) Assay Guide

  2026-09-22

  A scenario-based guide to using CHI3L1-IN-5 (Compound Z17, CAS No. 2249043-42-1; SKU C8756) in astrocyte viability, NF-κB, amyloid-β uptake, and lysosomal assays. It covers dose design, vehicle controls, interpretation, storage, and practical vendor-selection criteria for more defensible neuroinflammation experiments.

• (R,S)-Anatabine Workflow for Alzheimer’s Research

  2026-09-21

  Build a stronger Alzheimer’s disease workflow around (R,S)-Anatabine by pairing soluble Aβ measurements with APP processing, BACE-1, and NF-κB readouts. This practical guide separates evidence-backed findings from pilot parameters and shows how to troubleshoot solvent, timing, and assay-specific failures.

• JSH-23 as a Mechanistic NF-κB Research Probe

  2026-09-21

  JSH-23 is an NF-κB inhibitor for distinguishing p65-dependent transcription from upstream IκB turnover. This article develops a causal assay strategy connecting macrophage NF-κB signaling, NLRP3 biology, and kidney-injury models.

• Diuron-Induced Acute Renal Injury: JAK2/STAT1

  2026-09-20

  A 2025 study combines network toxicology, molecular docking, transcriptomic validation, and HK-2 cell experiments to investigate how Diuron may contribute to acute kidney injury. Its results identify JAK2/STAT1 signaling as a mechanistically relevant pathway and provide a framework for interpreting pesticide-associated renal toxicity.

• Tacrine hydrochloride hydrate in AD research

  2026-09-19

  Tacrine hydrochloride hydrate provides a quantitative benchmark for cholinesterase inhibition, cholinergic signaling, and neuroprotection assays. This workflow-focused guide shows how to use Tetrahydroaminacrine across enzyme, cell, and Alzheimer’s disease research while controlling solvent, exposure, and hepatotoxicity-related confounders.

• Tetrandrine Alkaloid: From Channels to Translation

  2026-09-18

  Tetrandrine is more than a natural-product listing: it is a mechanistically useful calcium-channel modulator for connecting membrane transport, cellular signaling, and translational experimental design. This article outlines how to validate its effects, select practical formats, and interpret cross-domain evidence without overstating what computational or in vitro findings can prove.

• JSH-23: A Mechanistic NF-κB Inhibitor

  2026-09-18

  JSH-23 is a small-molecule NF-κB inhibitor that suppresses p65 nuclear localization and DNA binding without preventing IκB degradation. It is a research tool for inflammation research, macrophage assays, and a cisplatin-induced acute kidney injury model, but its findings should not be treated as clinical evidence.

7889 records 1/526 page Next 12345 下5页 Last page